Moleculin Biotech, Inc. short interest in 2023
In 2023, Moleculin Biotech, Inc.'s disclosed short interest ran from 0.27% of shares outstanding on 13 Jan 2023 to 1.06% on 29 Dec 2023, a change of +0.79 percentage points. The year's high was 1.14% on 15 Dec 2023 and its low 0.03% on 31 May 2023, averaging 0.39% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.75 days on 15 Dec 2023. Full history: Moleculin Biotech, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2025
2023 in figures
- Start of year
- 0.27% (13 Jan 2023)
- End of year
- 1.06% (29 Dec 2023)
- Change
- +0.79 pp
- High
- 1.14% (15 Dec 2023)
- Low
- 0.03% (31 May 2023)
- Average
- 0.39%
- Highest days to cover
- 2.75 (15 Dec 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.27% | 1.33 | |
| 31 Jan 2023 | 0.14% | 1.00 | |
| 15 Feb 2023 | 0.22% | 1.00 | |
| 28 Feb 2023 | 0.15% | 1.57 | |
| 15 Mar 2023 | 0.13% | 1.00 | |
| 31 Mar 2023 | 0.10% | 1.00 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 0.08% | 1.00 | |
| 28 Apr 2023 | 0.06% | 1.00 | |
| 15 May 2023 | 0.07% | 1.00 | 10-Q filed, results (8-K) |
| 31 May 2023 | 0.03% | 1.00 | |
| 15 Jun 2023 | 0.06% | 1.00 | |
| 15 Aug 2023 | 0.52% | 2.69 | 10-Q filed, results (8-K) |
| 29 Sep 2023 | 0.60% | 1.97 | |
| 13 Oct 2023 | 0.27% | 1.02 | |
| 31 Oct 2023 | 0.62% | 1.00 | |
| 15 Nov 2023 | 1.00% | 1.45 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 0.85% | 2.71 | |
| 15 Dec 2023 | 1.14% | 2.75 | |
| 29 Dec 2023 | 1.06% | 1.17 |
See also: Moleculin Biotech, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.